Wayland, MA, United States of America

Jiaquan Wu


 

Average Co-Inventor Count = 2.7

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Jiangyin, CN (2019)
  • Wayland, MA (US) (2020 - 2023)

Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Jiaquan Wu in Pharmaceutical Science

Introduction

Jiaquan Wu is an accomplished inventor based in Wayland, MA (US). He has made significant contributions to the field of pharmaceutical preparations, holding a total of 4 patents. His work focuses on developing innovative solutions for cancer treatment, particularly targeting lung cancer.

Latest Patents

Wu's latest patents include a pharmaceutical composition and preparation method that utilizes an EGFR inhibitor (C-005). This composition is designed for the treatment of cancer, specifically non-small cell lung cancer. Another notable patent is for a selective CDK4/6 inhibitor, which can be used to treat or prevent diseases modulated by CDK4/6. These advancements highlight his commitment to improving therapeutic options in oncology.

Career Highlights

Jiaquan Wu is currently associated with Wuxi Shuangliang Biotechnology Co., Ltd. His role in this company allows him to further his research and development efforts in the pharmaceutical industry. His innovative approaches have positioned him as a key figure in the development of new cancer therapies.

Collaborations

Wu collaborates with talented individuals such as Shenshuang Jin and Shuai Zhang. Their combined expertise enhances the research and development efforts within their organization.

Conclusion

Jiaquan Wu's contributions to pharmaceutical science demonstrate his dedication to advancing cancer treatment. His innovative patents and collaborative efforts are paving the way for new therapeutic options in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…